Home > Dermatology > SPIN 2022 > Best of the Posters > Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib

Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib

Presented By
Prof. Mark Lebwohl , Icahn School of Medicine at Mount Sinai, NY, USA
Conference
SPIN 2022
Trial
Phase 3, POETYK PSO-1, POETYK PSO-2
Doi
https://doi.org/10.55788/93769d25
In a special analysis of safety data from phase 3 trials on deucravacitinib, increased frequency of major cardiovascular events (MACE) or venous thromboembolism (VTE) was not found compared with apremilast therapy. Even though many participants had an elevated cardiovascular (CV) risk at baseline, event rates were low and constant over longer drug exposure. As the diagnosis of psoriasis has been linked to an increased risk of MACE and thromboembolic events, knowledge about a potential further increase of risk through anti-inflammatory medication is important [1,2]. In this context, Prof. Mark Lebwohl (Icahn School of Medicine at Mount Sinai, NY, USA) and colleagues investigated exposure-adjusted incidence rates of MACE and VTE in the treatment of psoriasis with the TYK2 inhibitor deucravacitinib [1]. The analysis was performed on data from the phase 3 POETYK PSO-1 and PSO-2 studies (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on